Table 1.

Summary of trial characteristics of the included studies for the pooled analysis

Characteristic	All patients	Gem/Cis	Ro96	RC57	ACCEPT	RASH
Number of patients, n	912	190	188	274	115	145
Treatment arm		A: Gem/Cis B: Gem	A: Cap/Gem B: Cap/Ox C: Gem/Ox	A: Cap/Erlo-Gem B: Gem/Erlo-Cap	A: Gem/Afa B: Gem	A: Gem/Erlo B: Gem/Erlo-FOLFIRINOX
Phase of trial		III	II	III	II	II
Primary endpoint		OS	PFS after 3 months	TTF after 1st and 2nd line therapy	OS	1-year survival rate in rash-positive patients ≥ 40%
Recruiting period	12/1997–01/2017	12/1997–01/2002	07/2002–06/2004	05/2006–12/2008	04/2013–01/2017	07/2012–07/2015
UICC-Stage	III–IV	III–IV	III–IV	III–IV	IV	IV

Gem Gemcitabine, Cis Cisplatin, Cap Capecitabine, Ox Oxaliplatin, Erlo Erlotinib, Afa Afatinib, OS overall survival, PFS progression-free survival, TTF time to treatment failure